Are cinnarizine and betahistine safe to use during the first trimester of pregnancy?

Safety of Cinnarizine and Betahistine in First Trimester Pregnancy

Neither cinnarizine nor betahistine can be definitively recommended as safe during the first trimester of pregnancy due to insufficient human safety data, though limited available evidence does not suggest major teratogenic risk.

Evidence Assessment

Cinnarizine

The most recent and relevant guideline evidence addresses cinnarizine specifically in the context of pregnancy:

First-line antihistamines with established safety profiles include cinnarizine for nausea and vomiting in pregnancy 1. The 2024 BJOG guideline explicitly lists cinnarizine among H1 antihistamines (alongside promethazine, cyclizine, and dimenhydrinate) that have been reported safe with no increased risk of teratogenesis or adverse pregnancy outcomes based on Cochrane review data.

However, the FDA drug label for cinnarizine (meclizine class) notes that animal studies showed fetal malformations in rats at doses approximately 2 times the human dose, though epidemiological studies in humans have not identified an association with major birth defects 2.

Betahistine

The evidence for betahistine is more limited:

• No specific mention in major pregnancy guidelines 3, 4, 3, 4 addressing antihistamine safety
• The FDA drug label states betahistine should be used during pregnancy only if clearly needed, with particular concern about its ability to contract uterine muscle 5
• Recent observational data (2025): A retrospective cohort of 40 pregnant women exposed to betahistine (90% in first trimester, 75% receiving 48mg daily) showed no major congenital malformations among 36 live births, though 5 babies (13.9%) had minor malformations 6
• Earlier case series (2018): Among 20 live births with betahistine exposure, there was 1 major and 2 minor congenital malformations 7

Clinical Recommendation Algorithm

When Treatment is Necessary:

1. First choice: Cinnarizine can be used if antiemetic therapy is required, as it appears in established pregnancy guidelines with documented safety data 1

2. Betahistine: Use with caution - Reserve for situations where:

   • Cinnarizine or other first-line antihistamines have failed
   • The clinical benefit clearly outweighs theoretical risks
   • The patient is counseled about limited human data

3. Avoid if possible during weeks 3-8 (organogenesis period) when teratogenic risk is highest 4

Important Caveats

• The small sample sizes in betahistine studies (40 and 27 patients respectively) 6, 7 mean these findings cannot confirm safety - they simply don't detect a signal with current data
• Betahistine's uterine contractility effects 5 raise theoretical concerns about miscarriage risk, though not substantiated in available case series
• Both medications lack the robust epidemiological data (large birth registries, case-control studies) that support second-generation antihistamines like loratadine and cetirizine 4

Safer Alternatives to Consider

If treating vertigo or nausea in first trimester, consider these better-studied options first:

• Chlorpheniramine (long safety record) 3
• Loratadine or cetirizine (FDA Pregnancy Category B with extensive human data) 3
• Promethazine or cyclizine (established safety for nausea/vomiting) 1